AlloVir Inc (ALVR)       3.9  -0.03 (-0.76%)

3.9  -0.03 (-0.76%)

US0198181036 - Common Stock - After market: 3.9 0 (0%)


Fundamental Rating

Taking everything into account, ALVR scores 3 out of 10 in our fundamental rating. ALVR was compared to 643 industry peers in the Biotechnology industry. The financial health of ALVR is medium. Also its profitability is quite bad. ALVR has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating


ALVR has negative profitability rations, so we won't be analyzing them here.
ALVR has a Return On Assets of -80.01%. This is below the industry average of -39.12%. 82% of the industry peers outperform ALVR.

The Piotroski-F score of ALVR is 3.00. This is a low score and indicates issues in the health and profitability of ALVR.
VS Industry

ROA (-80.01%) VS Industry: 18% outperformed.

-1,225.00
63.37

Valuation

Valuation Rating


With a price book ratio of 1.31, ALVR is valued correctly.
Compared to an average industry price book ratio of 1.68, ALVR is valued in line with its industry peers.

ALVR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALVR. No positive earnings are expected for the next year.
VS Industry

Price/Book (1.31) VS Industry: 57% outperformed.

758.07
0.05

Growth

Growth Rating


ALVR is expected to show a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 279.73% yearly.
Based on estimates for the next 5 years, ALVR will show a decrease in Earnings Per Share. The EPS will decrease by -1.38% on average per year.

ALVR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -101.06%.
The Revenue for ALVR has decreased by -100.00% in the past year. This is quite bad

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -101.06% -9.45% -5.15% -1.51% -1.38%
RevenueN/A N/A -100% -100% 142.54% 405.09% 279.73%

Health

Health Rating


ALVR has a Current Ratio of 11.08. This indicates that ALVR is financially healthy and has no problem in meeting its short term obligations.
The Current Ratio of ALVR is much better than the industry average of 7.23.
ALVR has a Quick Ratio of 11.08. This indicates that ALVR is financially healthy and has no problem in meeting its short term obligations.
The Quick Ratio of ALVR is much better than the industry average of 6.94.

ALVR has a Altman-Z score comparable to the industry average, which is at 0.61.
Compared to an average industry Debt to Equity Ratio of 0.00, ALVR is more dependent on financing than its industry peers.
Based on the Altman-Z score of 0.09, we must say that ALVR is in the distress zone and has some risk of bankruptcy.
ALVR has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of ALVR.
VS Industry

Debt/Equity (0) VS Industry: 39% outperformed.

39.31
-10.77

Quick Ratio (11.08) VS Industry: 66% outperformed.

0.04
142.31

Current Ratio (11.08) VS Industry: 66% outperformed.

0.05
142.31

Altman-Z (0.09) VS Industry: 47% outperformed.

-844.57
1,290.64

Dividend

Dividend Rating


No dividends for ALVR!.

ALVR Daily chart

AlloVir Inc3.9

NASDAQ:ALVR (6/30/2022, 7:00:01 PM)-0.03 (-0.76%)

After market: 3.9 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 05-05 2022-05-05/bmo Earnings (Next) 08-04 2022-08-04
Ins Owners 7.52% Inst Owners 42.68%
Market Cap 250.84M Analysts 84
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 1.31
EV/EBITDA -0.27
Profitability
ROA -80.01% ROE N/A
PM N/A Asset Turnover N/A
Growth
EPS 1Y -101.06% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -38%
EPS Next Y -9.45% EPS Next 2Y -5.15%
EPS Next 3Y -1.51% EPS Next 5Y -1.38%
Revenue growth 1Y -100% Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year -100% Revenue Next 2Y 142.54%
Revenue Next 3Y 405.09% Revenue Next 5Y 279.73%
Health
Current Ratio 11.08 Quick Ratio 11.08
Altman-Z 0.09 F-Score 3
Debt/Equity N/A
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA